Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIL or NK cell immunotherapy after complete remission in small-cell lung cancer
ChiCTR1800017861Phase 2Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous activated lymphocytes and Natural Killer Cells in small cell lung cancer (SCLC) (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Overall survival. Started Sep 2018; status: recruiting.
02
Drugs
autologous activated lymphocytesNatural Killer Cells
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR1800017861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017861.